Medicines for Europe and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have conducted a study into the potential second-wave of COVID-19 in Europe.
Working with the consultancy Kearney, the study investigated:
“…three illustrative scenarios of how demand for critical intensive care medicines may develop during autumn – the timeframe where a second COVID-19 wave currently appears to be most likely based on industry clinical experts’ consensus. To identify where medicine shortage risks are likely, a further analysis conducted by Kearney compared the data with the supply/ manufacturing plans of key European pharmaceutical companies. The study also suggests that there is currently no data that highlights insufficient levels of key ingredients to manufacture the medicines.”
Critical to the success of any industry strategy is the continuation of supply. EFPIA says:
“The conclusions provide clear evidence of the need for more detailed planning across Europe. Considering the industry analysis, based on the experts’ hypotheses, shortages across Europe during the summer months are less likely. However, in the event of a second wave in autumn, there are supply risks for Europe, most poignantly in neuromuscular blockers.”
Read the full study here.